Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.

Mazieres J, Cropet C, Montané L, Barlesi F, Souquet PJ, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Trédaniel J, Jaffro M, Collot S, Ferretti GR, Tiffon C, Mahier-Ait Oukhatar C, Blay JY.

Ann Oncol. 2020 Feb;31(2):289-294. doi: 10.1016/j.annonc.2019.10.022. Epub 2020 Jan 3.

PMID:
31959346
2.

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.

Mehlman C, Cadranel J, Rousseau-Bussac G, Lacave R, Pujals A, Girard N, Callens C, Gounant V, Théou-Anton N, Friard S, Trédaniel J, Blons H, Dujon C, Duchemann B, Schischmanoff PO, Chinet T, Giroux Leprieur E.

Lung Cancer. 2019 Nov;137:149-156. doi: 10.1016/j.lungcan.2019.09.019. Epub 2019 Sep 28.

PMID:
31600593
3.

Peripheral arterial disease and systematic detection of circulating tumor cells: rationale and design of the DETECTOR prospective cohort study.

Yannoutsos A, Fontaine M, Galloula A, Damotte D, Chatellier G, Paterlini-Bréchot P, Meyer G, Pastre J, Duchatelle V, Marini V, Schwering KL, Lazareth I, Ghaffari P, Stansal A, Sanson H, Labrousse C, Beaussier H, Nasr NB, Zins M, Salmeron S, Messas E, Lajonchère JP, Emmerich J, Priollet P, Trédaniel J.

BMC Cardiovasc Disord. 2019 Sep 13;19(1):212. doi: 10.1186/s12872-019-1193-1.

4.

Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer.

Fournel L, Wu Z, Stadler N, Damotte D, Lococo F, Boulle G, Ségal-Bendirdjian E, Bobbio A, Icard P, Trédaniel J, Alifano M, Forgez P.

Cancer Lett. 2019 Nov 1;464:5-14. doi: 10.1016/j.canlet.2019.08.005. Epub 2019 Aug 9.

PMID:
31404614
5.

Nivolumab-refractory patients with advanced non-small-cell lung cancer.

Costantini A, Fallet V, Corny J, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Brosseau S, Wislez M, Tredaniel J, Cadranel J.

Lung Cancer. 2019 Apr;130:128-134. doi: 10.1016/j.lungcan.2019.01.015. Epub 2019 Feb 14.

6.

Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody.

Wu Z, Fournel L, Stadler N, Liu J, Boullier A, Hoyeau N, Fléjou JF, Duchatelle V, Djebrani-Oussedik N, Agopiantz M, Ségal-Bendirdjian E, Gompel A, Alifano M, Melander O, Trédaniel J, Forgez P.

Cancer Lett. 2019 Mar 1;444:147-161. doi: 10.1016/j.canlet.2018.12.007. Epub 2018 Dec 21.

PMID:
30583074
7.

Synchronous Oligometastatic Lung Cancer Deserves a Dedicated Management.

Loi M, Mazzella A, Mansuet-Lupo A, Bobbio A, Canny E, Magdeleinat P, Régnard JF, Damotte D, Trédaniel J, Alifano M.

Ann Thorac Surg. 2019 Apr;107(4):1053-1059. doi: 10.1016/j.athoracsur.2018.10.029. Epub 2018 Nov 23.

PMID:
30476480
8.

Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.

Meyer G, Besse B, Doubre H, Charles-Nelson A, Aquilanti S, Izadifar A, Azarian R, Monnet I, Lamour C, Descourt R, Oliviero G, Taillade L, Chouaid C, Giraud F, Falcoz PE, Revel MP, Westeel V, Dixmier A, Tredaniel J, Dehette S, Decroisette C, Prevost A, Pichon E, Fabre E, Soria JC, Friard S, Stern JB, Jabot L, Dennewald G, Pavy G, Petitpretz P, Tourani JM, Alifano M, Chatellier G, Girard P.

Eur Respir J. 2018 Oct 4;52(4). pii: 1801220. doi: 10.1183/13993003.01220-2018. Print 2018 Oct.

PMID:
30262574
9.

[Analysis of immune microenvironment by multiplex immunohistochemistry in locally advanced non-small cell lung cancer: Principles and perspectives].

Boulle G, Velut Y, Boni A, Lupo A, Alifano M, Trédaniel J, Giraud P, Damotte D.

Cancer Radiother. 2018 Oct;22(6-7):688-693. doi: 10.1016/j.canrad.2018.07.031. Epub 2018 Aug 18. Review. French.

PMID:
30131267
10.

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer.

Costantini A, Corny J, Fallet V, Renet S, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Nguenang M, Jouveshomme S, Wislez M, Tredaniel J, Cadranel J.

ERJ Open Res. 2018 Apr 20;4(2). pii: 00120-2017. doi: 10.1183/23120541.00120-2017. eCollection 2018 Apr.

11.

Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians.

Saffroy R, Morère JF, Bosselut N, Innominato PF, Hamelin J, Trédaniel J, Masse S, Dussaule-Duchatelle V, Balaton A, Validire P, Guettier C, Bouchahda M, Lemoine A.

Oncotarget. 2017 Feb 7;8(31):50792-50803. doi: 10.18632/oncotarget.15132. eCollection 2017 Aug 1.

12.

Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank.

Stücker I, Martin D, Neri M, Laurent-Puig P, Blons H, Antoine M, Guiochon-Mantel A, Brailly-Tabard S, Canonico M, Wislez M, Trédaniel J; WELCA study group.

BMC Public Health. 2017 Apr 17;17(1):324. doi: 10.1186/s12889-017-4191-1.

13.

Challenges in Diagnosis and Treatment of Lung Cancer in People with Intellectual Disabilities: Current State of Knowledge.

Satgé D, Kempf E, Dubois JB, Nishi M, Trédaniel J.

Lung Cancer Int. 2016;2016:6787648. Epub 2016 Sep 26. Review.

14.

Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.

Fiteni F, Vernerey D, Bonnetain F, Vaylet F, Sennélart H, Trédaniel J, Moro-Sibilot D, Herman D, Laizé H, Masson P, Derollez M, Clément-Duchêne C, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V.

Eur J Cancer. 2016 Jan;52:120-8. doi: 10.1016/j.ejca.2015.10.004. Epub 2015 Dec 10.

PMID:
26682871
15.

[Why screen for lung cancer in patients with arterial disease?].

Lederlin M, Trédaniel J, Priollet P.

J Mal Vasc. 2015 Dec;40(6):359-64. doi: 10.1016/j.jmv.2015.07.001. Epub 2015 Aug 12. Review. French.

PMID:
26276562
16.

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.

Couraud S, Souquet PJ, Paris C, Dô P, Doubre H, Pichon E, Dixmier A, Monnet I, Etienne-Mastroianni B, Vincent M, Trédaniel J, Perrichon M, Foucher P, Coudert B, Moro-Sibilot D, Dansin E, Labonne S, Missy P, Morin F, Blanché H, Zalcman G; French Cooperative Intergroup IFCT.

Eur Respir J. 2015 May;45(5):1403-14. doi: 10.1183/09031936.00097214. Epub 2015 Feb 5.

17.

Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.

Besse B, Le Moulec S, Mazières J, Senellart H, Barlesi F, Chouaid C, Dansin E, Bérard H, Falchero L, Gervais R, Robinet G, Ruppert AM, Schott R, Léna H, Clément-Duchêne C, Quantin X, Souquet PJ, Trédaniel J, Moro-Sibilot D, Pérol M, Madroszyk AC, Soria JC.

Clin Cancer Res. 2015 Apr 15;21(8):1896-903. doi: 10.1158/1078-0432.CCR-14-2082. Epub 2015 Jan 22.

18.

Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.

Younes M, Wu Z, Dupouy S, Lupo AM, Mourra N, Takahashi T, Fléjou JF, Trédaniel J, Régnard JF, Damotte D, Alifano M, Forgez P.

Oncotarget. 2014 Sep 30;5(18):8252-69.

19.

Diagnosis and standardized report for non-small cell lung cancer.

Revel MP, Carette MF, Torrent M, Trédaniel J.

Diagn Interv Imaging. 2014 Jul-Aug;95(7-8):727-38. doi: 10.1016/j.diii.2014.06.007. Epub 2014 Jul 9.

20.

Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.

Couraud S, Vaca-Paniagua F, Villar S, Oliver J, Schuster T, Blanché H, Girard N, Trédaniel J, Guilleminault L, Gervais R, Prim N, Vincent M, Margery J, Larivé S, Foucher P, Duvert B, Vallee M, Le Calvez-Kelm F, McKay J, Missy P, Morin F, Zalcman G, Olivier M, Souquet PJ; BioCAST/IFCT-1002 investigators.

Clin Cancer Res. 2014 Sep 1;20(17):4613-24. doi: 10.1158/1078-0432.CCR-13-3063. Epub 2014 Jul 10.

21.

[Individual lung cancer screening in practice. Perspectives on the propositions from the multidisciplinary group of the Intergroupe francophone de cancérologie thoracique, the Société d'imagerie thoracique and the Groupe d'oncologie de langue française].

Girard N, Gounant V, Mennecier B, Greillier L, Cortot AB, Couraud S, Besse B, Brouchet L, Castelnau O, Ferretti GR, Frappé P, Khalil A, Lefebure P, Laurent F, Liebart S, Margery J, Molinier O, Quoix E, Revel MP, Stach B, Souquet PJ, Thomas P, Trédaniel J, Lemarié E, Zalcman G, Barlési F, Milleron B; groupe de travail multidisciplinaire de l’Intergroupe francophone de cancérologie thoracique, de la Société d’imagerie thoracique et du Groupe d’oncologie de langue française.

Rev Mal Respir. 2014 Jan;31(1):91-103. doi: 10.1016/j.rmr.2013.10.641. Epub 2014 Jan 10. French. No abstract available.

PMID:
24461451
22.

Adenocarcinoma of the lung in Down syndrome: first clinical report.

Satgé D, Salmeron S, Homsi T, Réthoré MO, Tredaniel J.

Tumori. 2013 Jul-Aug;99(4):e169-71. doi: 10.1700/1361.15118.

PMID:
24326855
23.

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer.

Quoix E, Westeel V, Moreau L, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Sennelart H, Tredaniel J, Mennecier B, Morin F, Baudrin L, Milleron B, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique.

Eur Respir J. 2014 Jan;43(1):240-9. doi: 10.1183/09031936.00048213. Epub 2013 Oct 10.

24.

Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy.

Wu Z, Martinez-Fong D, Trédaniel J, Forgez P.

Front Endocrinol (Lausanne). 2013 Jan 17;3:184. doi: 10.3389/fendo.2012.00184. eCollection 2012.

25.

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de langue francaise (GOLF).

Couraud S, Cortot AB, Greillier L, Gounant V, Mennecier B, Girard N, Besse B, Brouchet L, Castelnau O, Frappé P, Ferretti GR, Guittet L, Khalil A, Lefebure P, Laurent F, Liebart S, Molinier O, Quoix E, Revel MP, Stach B, Souquet PJ, Thomas P, Trédaniel J, Lemarié E, Zalcman G, Barlési F, Milleron B; French lung cancer screening statement taskforce; groupe d'Oncologie de langue française.

Ann Oncol. 2013 Mar;24(3):586-97. doi: 10.1093/annonc/mds476. Epub 2012 Nov 7.

26.

[Targeted agents in the treatment of lung cancer].

Staudacher L, Teixeira L, Kempf E, Rousseau-Bussac G, Jouveshomme S, Cohen R, Beuzelin C, Jagot JL, Salmeron S, Trédaniel J.

Pathol Biol (Paris). 2012 Aug;60(4):246-53. doi: 10.1016/j.patbio.2012.05.011. Epub 2012 Jun 26. Review. French.

PMID:
22743094
27.

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.

Quoix E, Zalcman G, Oster JP, Westeel V, Pichon E, Lavolé A, Dauba J, Debieuvre D, Souquet PJ, Bigay-Game L, Dansin E, Poudenx M, Molinier O, Vaylet F, Moro-Sibilot D, Herman D, Bennouna J, Tredaniel J, Ducoloné A, Lebitasy MP, Baudrin L, Laporte S, Milleron B; Intergroupe Francophone de Cancérologie Thoracique.

Lancet. 2011 Sep 17;378(9796):1079-88. doi: 10.1016/S0140-6736(11)60780-0. Epub 2011 Aug 8.

PMID:
21831418
28.

Thymic metastasis from lung carcinoma.

Demondion P, Validire P, Trédaniel J, Gossot D.

Interact Cardiovasc Thorac Surg. 2011 May;12(5):848-9. doi: 10.1510/icvts.2010.257030. Epub 2011 Feb 8.

PMID:
21303866
29.

[A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)].

Tredaniel J, Mornex F, Barillot I, Diaz O, Hennequin C, Le Pechoux C, Lavole A, Giraud P, Souquet PJ, Teixeira L, Vaylet F, Zalcman G, Baudrin L, Morin F, Milleron B.

Rev Mal Respir. 2011 Jan;28(1):51-7. doi: 10.1016/j.rmr.2010.06.027. Epub 2011 Jan 11. French.

PMID:
21277474
30.

[PET-CT for evaluation of the solitary pulmonary nodule: an update].

Groheux D, Hindié E, Trédaniel J, Giraudet AL, Vaylet F, Berenger N, Moretti JL.

Rev Mal Respir. 2009 Dec;26(10):1041-55. Review. French.

PMID:
20032840
31.

Use of adjuvant chemotherapy in non-small cell lung cancer in routine practice.

Massard C, Tran Ba Loc P, Haddad V, Pignon JP, Girard P, Monnet I, Trédaniel J, Besse B, Soria JC.

J Thorac Oncol. 2009 Dec;4(12):1504-10. doi: 10.1097/JTO.0b013e3181bbf1c9.

32.

Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel.

De Marinis F, Eberhardt W, Harper PG, Sureda BM, Nackaerts K, Soerensen JB, Syrigos K, Trédaniel J.

J Thorac Oncol. 2009 Oct;4(10):1280-8. doi: 10.1097/JTO.0b013e3181b68e5a.

33.

[Atmospheric air pollution and lung cancer: epidemiologic data].

Trédaniel J, Aarab-Terrisse S, Teixeira L, Savinelli F, Fraboulet S, Gossot D, Hennequin C.

Rev Mal Respir. 2009 Apr;26(4):437-45; quiz 481, 484. French.

PMID:
19421096
34.

The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma.

Planchard D, Domont J, Taranchon E, Monnet I, Tredaniel J, Caliandro R, Validire P, Besse B, Soria JC, Fouret P.

Ann Oncol. 2009 Jul;20(7):1257-63. doi: 10.1093/annonc/mdn785. Epub 2009 Mar 17.

PMID:
19297315
35.

[Lung cancers in the elderly].

Trédaniel J, Savinelli F, Sergent G, Bousquet G, Le Maignan C, Hennequin C, Gossot D, Misset JL.

Bull Cancer. 2008 May 28;95 FMC Onco:F57-64. doi: 10.1684/bdc.2007.0536. French.

PMID:
18511368
36.

[Decision making process in oncology: rationale and delineation of a composite index of relative antitumoral efficacy (In-RATE)].

Marty M, Blay JY, Trédaniel J, Koscielny S, Hagège C, Asselain B, Goldwasser F, Misset JL.

Bull Cancer. 2008 Nov;95(11):1075-82. doi: 10.1684/bdc.2008.0738. French.

37.

An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients.

Trédaniel J, Becht C, Bekradda M, De Cremoux H, Alexandre J, Chomy F, Szyldergemajn S, Yataghene Y, Culine S.

Lung Cancer. 2009 Feb;63(2):259-63. doi: 10.1016/j.lungcan.2008.05.028. Epub 2008 Jul 16.

PMID:
18635285
38.

Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE).

Blay JY, Koscielny S, Trédaniel J, Asselain B, Goldwasser F, Misset JL, de Labareyre C, Hagège C, Bismut H, Marty M.

Crit Rev Oncol Hematol. 2007 Nov;64(2):106-14. Epub 2007 Jul 30.

PMID:
17681785
39.

[Abdominal pain during the course of lung cancer].

Ba O, Almeida F, Fondronnier C, Michalski M, Gossot D, Savinelli F, Le Maignan C, Misset JL, Trédaniel J.

Rev Pneumol Clin. 2007 Apr;63(2):100-3. French.

PMID:
17607214
40.

[IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer].

Westeel V, Lebitasy MP, Mercier M, Girard P, Barlesi F, Blanchon F, Tredaniel J, Bonnette P, Woronoff-Lemsi MC, Breton JL, Azarian R, Falcoz PE, Friard S, Geriniere L, Laporte S, Lemarie E, Quoix E, Zalcman G, Guigay J, Morin F, Milleron B, Depierre A; Intergroupe Francophone de Cancerologie Thoracique (IFCT).

Rev Mal Respir. 2007 May;24(5):645-52. French.

PMID:
17519819
41.

[Epidemiology of lung cancer. The tobacco epidemic].

Trédaniel J.

Rev Mal Respir. 2006 Nov;23(5 Pt 3):16S7-16S10. Review. French.

PMID:
17268329
42.

Long-term results of endobronchial brachytherapy: A curative treatment?

Hennequin C, Bleichner O, Trédaniel J, Quero L, Sergent G, Zalcman G, Maylin C.

Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):425-30. Epub 2006 Nov 2.

PMID:
17084547
43.

[The consequences of passive smoking in adults].

Trédaniel J, Savinelli F, Vignot S, Bousquet G, Le Maignan C, Misset JL.

Rev Mal Respir. 2006 Apr;23 Suppl 2:4S67-4S73. Review. French.

PMID:
16733402
44.

Decision making process in oncology practice: is the information available and what should it consist of?

Trédaniel J, Blay JY, Goldwasser F, Asselain B, Koscielny S, de Labareyre C, Balogh N, Bismut H, Misset JL, Marty M.

Crit Rev Oncol Hematol. 2005 Jun;54(3):165-70.

PMID:
15890267
45.

[Evidence based pneumology: 3rd update workshop to the SPLF. Smoking: from prevention to weaning].

Wirth N, Bohadana A, Spinosa A, Abou-Hamdan K, Raymond S, Martinet Y, Quantin X, Trédaniel J.

Rev Mal Respir. 2004 Dec;21(6 Pt 1):1197-201. Review. French. No abstract available.

PMID:
15793893
46.

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).

Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, Debieuvre D, Pujol JL, Tredaniel J, Clouet P, Quoix E.

Ann Oncol. 2005 Jan;16(1):90-6.

PMID:
15598944
47.

Direct treatment costs for patients with lung cancer from first recurrence to death in france.

Braud AC, Lévy-Piedbois C, Piedbois P, Piedbois Y, Livartovski A, Le Vu B, Trédaniel J, Reboul F, Brewer Y, Talbi S, Blanchon F, Paschen B, Durand-Zaleski I.

Pharmacoeconomics. 2003;21(9):671-9.

PMID:
12807368
48.

[Endobronchial brachytherapy: technique and indications].

Hennequin C, Bleichner O, Trédaniel J, Maylin C.

Cancer Radiother. 2003 Feb;7(1):33-41. Review. French.

PMID:
12648715
49.

[Mediastinal adenopathies and mediastinal tumors. Diagnostic approach].

Trédaniel J.

Rev Prat. 2000 Oct 1;50(15):1733-7. French. No abstract available.

PMID:
11116618
50.

A misleading pulmonary lesion in a patient with acute monoblastic leukemia.

Meignin V, Tredaniel J, Leblanc T, Daneshpouy M, Ray-Lunven AF, Zalcman G, Daniel MT, Janin A.

Leuk Lymphoma. 2000 Apr;37(3-4):457-9. No abstract available.

PMID:
10753000

Supplemental Content

Loading ...
Support Center